Advertisement Covidien establishes venture arm - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Covidien establishes venture arm

Covidien, a provider of healthcare products, has established Covidien Ventures, a corporate venture capital function. Covidien Ventures will invest in areas of strategic importance to the company with the goal of providing early exposure to innovative technologies and enhancing market intelligence in healthcare products.

Covidien Ventures will be managed by Daniel Sheehan, vice president of Corporate Venture Capital, who recently joined Covidien from Affinity Capital Management.

Mr Sheehan, who has 20 years of experience in venture capital, business development and investment banking, will direct the new fund and lead the investment process for Covidien.

Amy Wendell, senior vice president of corporate strategy and business development, said: “Covidien Ventures will allow us to make early-stage investments and investigate emerging technologies in the healthcare areas of interest to Covidien. This exposure could potentially lead to our acquiring technology, intellectual property or start-up companies to expand our product portfolio and accelerate business growth.”